SIPRI: War in Ukraine boosts arms manufacturers' profits

SIPRI reports arms-makers' weapons and military services revenues hit $679 billion in 2024, an inflation-adjusted increase of 5.9% year-on-year driven largely by demand tied to the war in Ukraine. Regional splits show US-based firms (39 companies) account for nearly half of sales but grew modestly (+3.8%), while 26 European firms rose 13% and German companies surged 36% (four German firms generated $14.9bn); Rheinmetall earned 47% more and KNDS saw orders jump 40% (revenue +14%). Russia shifted to a war economy—domestic production of 152mm shells rose 420% (250,000 to 1.3m between 2022–24)—while Chinese arms revenues fell ~10% amid corruption-related order cancellations; top global firms remain led by Lockheed Martin, RTX, Northrop Grumman, BAE and General Dynamics.

Analysis

Market structure: The SIPRI data confirms a bifurcation — incumbent US primes (LMT, NOC, RTX, GD) hold ~50% share and benefit from durable DoD budgets, while European specialists (Rheinmetall, Diehl) are capturing a near-term 13% regional revenue surge and Germany +36% driven by restocking and ammo orders. Demand is front-loaded (replenishment + replacement), creating 12–36 month lead times and pricing power for specialized munitions and ground systems; Chinese OEMs are the primary near-term losers (-10% revenue) from corruption-driven order freezes.

Risk assessment: Tail scenarios include rapid de-escalation/peace (>=20% drop in European/US orders within 12 months) causing 15–30% revenue downgrades for exposed manufacturers, or expanded sanctions/parts chokepoints raising production risk and input inflation (steel, electronics, rare earths). Immediate (days) volatility tied to contract announcements and FX flows; short-term (3–12 months) earnings rehypothecation from order timing; long-term (2–5 years) demand depends on NATO sustainment budgets and industrial capacity rebuilds. Hidden dependency: single-source electronics and artillery-capacity constraints can bottleneck delivery despite order momentum.

Trade implications: Tactical overweight US primes via LMT/NOC (2–3% portfolio each) with 9–12 month horizons; use defined-risk bullish call spreads (buy 12m 10% ITM / sell 25% OTM) to lever upside while capping theta. Add selective European exposure (RHM.DE) sized 1–2% versus short FXI (China ETF) to capture regional divergence; stagger entries over 4–8 weeks around EU budget confirmations. Protect positions with 1–2% cost collars if order intake falls >15% q/q.

Contrarian angles: Consensus underestimates inventory-cycle mean reversion — once NATO/EU stocks rebuilt (12–24 months) commodity-driven margin compression and order normalization are likely, creating a 20–35% downside risk from peak multiples. Historical analog: post-2014 defense spikes saw multi-year plateaus; unintended consequence — accelerated domestic capacity may crowd out exports and cap long-term growth. Exit/trim if a name rallies >25% pre-earnings or if headline risk (ceasefire talks, major budget rollback) materializes.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in LMT with a 9–12 month horizon; implement a 12-month call spread (buy 1x 10% ITM, sell 1x 25% OTM) to cap premium and target asymmetric upside if US orders persist.
• Initiate a 2–3% long in NOC with same 12-month call-spread structure; size Vega risk to no more than 1.5% of portfolio and re-evaluate after Q2/FY25 order announcements.
• Add a 1–2% tactical long in RHM.DE (Rheinmetall) and pair with a 1–2% short position in FXI (China ETF) to exploit Europe-vs-China defense divergence; enter staggered over 4–8 weeks and trim if RHM.DE rises >25% or FXI falls >15%.
• Buy 6–12 month protective collars (1–2% portfolio cost) across positions that widen into earnings windows; unwind collars if order intake beats by >10% q/q or if share rallies >25% from entry.
• Do not initiate material exposure to Chinese defense-equivalent names or Asia-heavy defense suppliers until corruption/order-clearance signals normalize; revisit after 60–90 days of confirmed contract resumption or reversal of procurement cancellations.